Depot Medroxyprogesterone Acetate (Depo-Provlera) as a Contrac·eptive Preparation by Bloch, Basil
17 July 1971 S.A. MEDICAL JOURNAL 777
D:epot Medroxyprogesterone Acetate
(Depo-Provlera) as a Contrac·eptive Preparation *
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SUMMARY
Experience with depot medroxyprogesterone acetate as a
contraceptive preparation in 7 335 patients for a total of
38 714 months over a 3-year period is described. The
discontinuation rate was 18'3% and the failure rate 0'35
per 100 women-years of use. This compares very well with
all other methods of contraception.
The only troublesome side-effect was brealChrough
bleeding which diminished with continued use. The
aetiology of this menstrual disruption and methods of
prevention and treatment are discussed. The role of this
preparation in present-day contraceptive practice is out-
lined.
I. Inhibition of the secrelion of gonadotrophic hor-
mones, particularly luteinizing hormone, and thereby
preventing ovulation.'" There is no influence on the
secretion of growth or thyrotrophic hormones.'
2. Alteration of endometrial histology which, in turn,
prevents nidation.'" It would also appear from studies
on lower animals that myometrial activity is signifi-
cantly reduced in the presence of DMPA.'o
3. Increase in the viscosity and alteration of the pH




It will be seen that the number of patients who have
discontinued the use of this method is I 344. The reasons
for discontinuation are as follows:
The dropout or discontinuation rate is thus 18'3°~,
which compares well with the figures reported by other
investigators listed in Table n.
All patients were examined fully before commencement
of treatment, and the examination was repeated annually.
A Papanicolaou smear was done as a routine whenever
this was possible. Only those patients considered clinically
free from gynaecological and endocrine disorders were
given the DMPA and only patients of proven fertility were
included in the study. An aqueous suspension of DMPA
50 mg/ ml was used. The dosage was 150 mg (3 mO, given
every 90 days.
The programme has continued over the past 3 years and
at present involves 5 991 patients. Table I sets out our
experience of this method for a total of 7335 patients who
















Change requested by patient
Change for medical reasons
Planned pregnancy
Unplanned pregnancy
Moved away from clinic
Reason unknown
Prevention of contraception is thought to be due to
a number of complementary actions:
Mode of Action
'Date received: 19 October 1970.
. Upjolln, Johannesburg.
S. Afr. Med. l., 45, 777 (1971).
The search for the so-called 'universal' or 'perfect' contra-
ceptive preparation continues. It was inevitable that, fol-
lowing 1he successful use of hormonal agents taken orally
for the control of ovulation, efforts to avoid a daily dosage
schedule--and the accompanying risk of a pregnancy due
to forgotten pills-should be initiated and pursued. One
avenue that clearly held promise was the use of long-
acting or depot injectable steroid hormones; and com-
binations of long-acting oestrogens and progestogens have
been tried with varying degrees of success. More recently.
long acting progestogens alone have been tried, and this
article deals with experience with the latter, using 17 alpha-
hydroxy-6 alpha methylprogesterone acetate, better known
as medroxyprogesterone acetate (DMPA) or Depo-
Provera. t
Depo-Provera has been extensively used in the treat-
ment of threatened and habitual abortion and endometrio-
sis, and recently it has been found to be of use in endo-
metrial, renal and breast carcinoma.
As a progestational agent, DMPA is 20 - 30 times more
effective than progesterone in the inhibition of ovulation in
rabbits.' It is also 10·5 times as actIve as progesterone when
checked by the Clauberg assay for endometrial stimulation
in immature rabbits.'
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TABLE 11. DISCONTINUATION RATES Failure Rate
These figures must, however, be compared with the
discontinuation rates of other commonly used methods of










346 out of 1 730
316 out of 1 580
96 out of 480
57 out of 100
28 out of 148
239 out of 1 6-:5









The unplanned pregnancy or failure rate in this series
is 0·35 per 100 woman-years of use. Again, this must be
assessed in the light of figures reported by other investi-
gators (Table IV).
The reported failure rates vary between 0·00 and 2·72
per 100 woman-years of use, and, to be of statistical value,
this failure rate must be seen in its true light, i.e. by
comparison with the other commonly used and effective
methods of contraception. These are tabulated in Table V.
TABLE V. FAILURE RATES



























Total woman- per 100 woman-
Dose No. of patients months of use years
150 mg/3 months 1730 15584 0'40
300 mg/6 months 1580 30900 2·72
150 mg/3 months 480 4528 0·00
150 mg!3 mont.hs 298 3010 0·00
150 mg/3 months 100 975 0·00
(postpartum)
150 mg/3 months 148 1285 0·00
150 mg/3 months 7335 38714 0'35
s
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The common side-effects are given in Table VI. The
commonest and most troublesome side-effect will be seen
to be disruption of the menstrual pattern with bleeding
problems (breakthrough bleeding). The other problems
which arise are usually relatively minor ones, and include
weight gain, headaches, nervousness, loss of libido, nausea,
dizziness, vaginal discharge, breast problems and skin
rashes. It has been observed that the incidence of bleeding
problems gradually decreases with the continuation of
treatment. This is illustrated in the following table:
TABLE VII. BLEEDING PROBLEMS
% days wi~h breakthrough bleeding










• Injection period 90 days.
Treatment of Bleeding Problems
The treatment of side-effects for practical purposes in-
volves only the management of bleeding problems. It is
most important, before attributing all menstrual problems
to the use of the drug, to be absolutely certain that no
coexistent pathology exists. This applies particularly to
pelvic infection, cerVICItis. moniliasis, trichomoniasis and
gynaecological malignancies. These conditions, if suspected
clinically, should be diagnosed and treated by the appro-
priate methods and with the usual drugs before assuming
that the D\1PA is causing the menstrual disorganizati9n.
Only in this way will the best results be obtained from this
method of contraception, and in addition, no serious co-
existent disease will be missed.
If, however, the bleeding problems are found to be due
to the drug, treatment is based on the assumption that the
bleeding is caused by the drug's potent anti-oestrogenic
effect which so lowers ovarian oestrogen secretion that
endometrial disruption follows. Treatment has been with
oestrogens, usually by the oral route, and the recommended
dosage is stilboestrol I - 3 mg daily, ethinyloestradiol 0·05 -
0'1 mg daily, or Premarin 1·25 - 2·5 mg daily, usually given
for from 5 to 10 days.
It is important to warn patients of this possibility before
starting treatment, to emphasize that these problems almost
invariably improve with the passage of time and con-
tinuation of treatment, and to reassure them while these
problems are troublesome.
Re-establishment of Fertility
This can only be judged by the criteria commonly em-
ployed for determining the occurrence of ovulation. These
criteria include the return of natural menstruation, vaginal
smear patterns, monthly endometrial biopsies, cervical
mucous testing, pregnanediol estimations and also subjec-
tive findings.
Using the above criteria (of which at least 3 must be
positive) it has been estimated" that 33°{, of patients ovu-
lated within 6 months of their last injection: Ihat 99°{,
of patients ovulated within one year of their last injection:
that ovulation was not always consistent and in some cases
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was sporadic for up to j 8 months; and that the interval for
re-establishment of fertility appeared umelated to dosage."
Effect on Lactation
In a recent comparative study" the conclusion arrived
at was that DMPA had given the most satisfactory results
in relation to milk yields, infant growth curves and lactose
and protein content of milk. There was a drop in the lipid
content. It was concluded that this type of contraception
was ideal in the postpartum period, as bleeding problems
were expected to some extent and thus did not cause
concern to these women.
The Problem of Thrombo-embolism
To date, there has been only one report" of a thrombosis
of the subclavian vein. In view of the large number of
women who have had this preparation at various times,
for various reasons and in varying doses, and also because
of the fact that no oestrogen is being administered, it
seems unlikely that thrombosis will be a major problem.
Breast Tumours
The occurrence of breast tumours in beagle bitches after
continuous administration of chlormadinone acetate
(Normenon) in doses of 0·5 mg daily, naturally poses this
question in regard to DMPA.
The findings at present are that mammary nodules have
been observed to occur after ]8 months of treatment in
beagle bitches known to be prone to their occurrence, but
not in monkeys. These dogs differ from humans in their
metabolism of DMPA and also in their propensity to
develop hypertrophic endometriosis, and these results
therefore cannot be extrapolated to humans. Furthermore,
breast nodules have not been reported in humans after
10 years of use for various indications, for periods extend-
ing up to 60 months.
However, it would seem to be necessary to impress upon
patients the advisability of the periodic breast examina-
tions which are recommended with any hormonal contra-
ceptive regime.
Advocated Use at Present
At present, because of the uncertainty in regard to
restoration of fertility, this method should not be used for
family spacing. Ideally, it should be confined to patients
who should not conceive for a long period of time, or
have any more children. This general category would
include the following large groups of patients:
1. Failure with or an inability to use other forms of
contraceptives.
2. Chronic illness where no further pregnancies are
desirable, e.g. TB, chronic renal disease.
3. 'Problem' patients with 'problem' families who will
not, or cannot, use other methods of contraception
reliably. Motivation is usually lacking or very poor
in these cases.
4. Patients where clinic attendance is a problem, due
to distance.
THOUGHTS FOR THE FUTURE
As the major problem with this preparation is a dis-
organization of the menstrual cycle, with the most trouble-
some side-effect being breakthrough bleeding, this would
appear to be the most urgent problem for investigation.
All findings suggest a lowering or absence of oestrogenic
effect on the target organs, particularly the endometrium
and vagina. To determine whether this effect is due to an
inhibition of endogenous oestrogen production by DMPA,
or due to the drug's effect overwhelming the end-organ
action of normal levels of circulating oestrogen, is impor-
tant; if the endogenous oestrogen level is low, perhaps
additional oestrogen should be given to prevent the
possible early development of oesteoporosis or arterio-
sclerosis.
This should be fairly easy to determine and is a priority
on a study set up in our series recentlY, and which we hope
to report on in the future.
This project was carried out in the Clinics of the East Cape
Division of the Family Planning Association of South Africa.
I wish to thank all members of the staff for their co-operation:
also the office staff of the Oasim Central Clinic, particularly
the Regional Secretary, Mrs M. Booker and the Education
Officer, Mrs H. Coetzee: and Messrs Upjohn (Pty) Ltd for the
initial supplies of Depo-Provera.
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